A phase I dose escalation study of ABI-007 [paclitaxel] with carboplatin as first-line therapy in patients with epithelial ovarian, primary peritoneal or fallopian tube carcinoma.

Trial Profile

A phase I dose escalation study of ABI-007 [paclitaxel] with carboplatin as first-line therapy in patients with epithelial ovarian, primary peritoneal or fallopian tube carcinoma.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2014

At a glance

  • Drugs Paclitaxel (Primary) ; Carboplatin
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Sponsors Abraxis BioScience
  • Most Recent Events

    • 02 Feb 2010 Actual patient number (6) added as reported by ClinicalTrials.gov.
    • 02 Feb 2010 Actual patient number (6) added as reported by ClinicalTrials.gov.
    • 12 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top